iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 565 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR EMA Recommends Extension of Indications for Daratumumab June 10, 2021 Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid... August 12, 2025 An Oncology Hospital at Home Model of Acute Care Shows Promise May 21, 2021 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Brain... September 30, 2021 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ ΑΔΕΝΑ Respuestas a sus preguntas sobre la vacuna contra el COVID-19 FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma New on NCI’s Websites for November 2024
